Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Type 1 Diabetes
Interventions
DEVICE

Florence D2A or similar closed loop glucose control system

Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone

DEVICE

CSII with CGM

Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)

Trial Locations (2)

A8036

Medical University of Graz, Graz

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge

All Listed Sponsors
collaborator

Medical University of Graz

OTHER

lead

University of Cambridge

OTHER

NCT02727231 - Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions | Biotech Hunter | Biotech Hunter